8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 27, 2026·SEC
Material company update
Feb 19, 2026·SEC
Guardant Health, Inc.(GH)Earnings, Financials & Key Ratios
GH•NASDAQ
Price updated Jun 19, 2026
AboutGuardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.Show more
- Revenue$982M+32.9%
- EBITDA-$397M+1.2%
- Net Income-$416M+4.6%
- EPS (Diluted)-3.32+6.7%
- Gross Margin64.46%+6.0%
- EBITDA Margin-40.38%+25.6%
- Operating Margin-44.43%+26.0%
- Net Margin-42.39%+28.2%
GH Key Insights
Guardant Health, Inc. (GH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 92 (top 8%)
- ✓Strong 5Y sales CAGR of 27.9%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 10.4% over 5 years
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GH Price & Volume
Guardant Health, Inc. (GH) stock price & volume — 10-year historical chart
Loading chart...
GH Growth Metrics
Guardant Health, Inc. (GH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years27.92%
3 Years29.75%
TTM39.56%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM0%
Return on Capital
10 Years-27.79%
5 Years-29.91%
3 Years-32.76%
Last Year-29.37%
GH Recent Earnings
Guardant Health, Inc. (GH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.85-5.5%
$0.81
Rev
$302M+8.1%
$279M
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$0.90-17.4%
$0.77
Rev
$281M+3.2%
$272M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.39+18.8%
$0.48
Rev
$265M-0.9%
$268M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.44+15.4%
$0.52
Rev
$232M-1.5%
$236M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.85vs $0.81-5.5% | $302Mvs $279M+8.1% |
| Q1 2026 | Feb 19, 2026 | $0.90vs $0.77-17.4% | $281Mvs $272M+3.2% |
| Q4 2025 | Oct 29, 2025 | $0.39vs $0.48+18.8% | $265Mvs $268M-0.9% |
| Q3 2025 | Jul 30, 2025 | $0.44vs $0.52+15.4% | $232Mvs $236M-1.5% |
Based on last 12 quarters of dataView full earnings history →
GH Peer Comparison
Guardant Health, Inc. (GH) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 FDMT | 504.97M | 9.66 | -3.99 | 2301.95% | -182.34% | -36.83% | 0.04 | |
 CGEN | 190.05M | 2.01 | 5.29 | 161.14% | 48.57% | 55.68% | 0.03 | |
 PACB | 434.84M | 1.40 | -0.77 | 3.89% | -80.34% | -488.45% | 141.98 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 BNGO | 3.83M | 1.17 | -0.24 | -7.37% | -109.95% | -71.38% | 0.16 |
Compare GH vs Peers
Guardant Health, Inc. (GH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GH Income Statement
Guardant Health, Inc. (GH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 49.84M | 90.64M | 214.38M | 286.73M | 373.65M | 449.54M | 563.95M | 739.02M | 982.02M | 1.08B |
Revenue Growth % | 97.4% | 81.85% | 136.52% | 33.75% | 30.32% | 20.31% | 25.45% | 31.04% | 32.88% | 39.56% |
Cost of Goods Sold | 31.62M | 43.21M | 70.72M | 92.53M | 122.91M | 156.32M | 227.05M | 289.8M | 349.01M | 379.2M |
COGS % of Revenue | 63.44% | 47.67% | 32.99% | 32.27% | 32.89% | 34.77% | 40.26% | 39.21% | 35.54% | - |
Gross Profit | 18.22M▲ 0% | 47.43M▲ 160.3% | 143.66M▲ 202.9% | 194.19M▲ 35.2% | 250.74M▲ 29.1% | 293.21M▲ 16.9% | 336.9M▲ 14.9% | 449.22M▲ 33.3% | 633.01M▲ 40.9% | 701.01M▲ 0% |
Gross Margin % | 36.56% | 52.33% | 67.01% | 67.73% | 67.11% | 65.23% | 59.74% | 60.79% | 64.46% | 64.9% |
Gross Profit Growth % | 483.17% | 160.26% | 202.88% | 35.18% | 29.12% | 16.94% | 14.9% | 33.34% | 40.91% | - |
Operating Expenses | 94.84M | 140.37M | 226.03M | 449.14M | 661.74M | 837.59M | 901.62M | 892.81M | 1.07B | 1.15B |
OpEx % of Revenue | 190.27% | 154.87% | 105.43% | 156.64% | 177.1% | 186.32% | 159.88% | 120.81% | 108.99% | - |
Selling, General & Admin | 69.27M | 89.66M | 139.73M | 299.28M | 398.52M | 463.78M | 451.03M | 545.06M | 706.07M | 781.86M |
SG&A % of Revenue | 138.99% | 98.92% | 65.18% | 104.38% | 106.66% | 103.17% | 79.98% | 73.75% | 71.9% | - |
Research & Development | 25.56M | 50.71M | 86.29M | 149.86M | 263.22M | 373.81M | 367.19M | 347.75M | 364.19M | 366.71M |
R&D % of Revenue | 51.29% | 55.95% | 40.25% | 52.27% | 70.45% | 83.15% | 65.11% | 47.06% | 37.09% | - |
Other Operating Expenses | 0 | 0 | 88K | 0 | 0 | 0 | 83.4M | 0 | 0 | 0 |
Operating Income | -76.61M▲ 0% | -92.94M▼ 21.3% | -82.37M▲ 11.4% | -254.95M▼ 209.5% | -411M▼ 61.2% | -544.38M▼ 32.5% | -564.73M▼ 3.7% | -443.59M▲ 21.4% | -436.3M▲ 1.6% | -447.56M▲ 0% |
Operating Margin % | -153.71% | -102.54% | -38.42% | -88.92% | -110% | -121.1% | -100.14% | -60.02% | -44.43% | -41.43% |
Operating Income Growth % | -74.73% | -21.32% | 11.37% | -209.51% | -61.21% | -32.45% | -3.74% | 21.45% | 1.64% | - |
EBITDA | -71.41M | -85.81M | -68.76M | -238.88M | -388.73M | -508.42M | -521.84M | -401.21M | -396.56M | -408.62M |
EBITDA Margin % | -143.26% | -94.67% | -32.08% | -83.31% | -104.04% | -113.1% | -92.53% | -54.29% | -40.38% | -37.83% |
EBITDA Growth % | -77.83% | -20.17% | 19.86% | -247.41% | -62.73% | -30.79% | -2.64% | 23.12% | 1.16% | 1.05% |
D&A (Non-Cash Add-back) | 5.21M | 7.14M | 13.61M | 16.07M | 22.27M | 35.96M | 42.88M | 42.39M | 39.74M | 38.94M |
EBIT | -80.51M | -82.97M | -68.54M | -241.14M | -381.89M | -650.87M | -476.19M | -432.51M | -413.64M | -429.92M |
Net Interest Income | -468K | 4.01M | 12.56M | 5.41M | 1.35M | 3.49M | 32.79M | 51.11M | 30.2M | 31.68M |
Interest Income | 2.23M | 5.27M | 13.74M | 10.17M | 3.93M | 6.07M | 35.37M | 53.69M | 34.09M | 36.13M |
Interest Expense | 2.7M | 1.25M | 1.18M | 4.77M | 2.58M | 2.58M | 2.58M | 2.58M | 3.9M | 4.45M |
Other Income/Expense | -6.6M | 8.72M | 12.65M | 9.05M | 26.53M | -109.07M | 85.96M | 8.51M | 18.76M | 13.18M |
Pretax Income | -83.21M▲ 0% | -84.22M▼ 1.2% | -69.72M▲ 17.2% | -245.9M▼ 252.7% | -384.47M▼ 56.3% | -653.45M▼ 70.0% | -478.76M▲ 26.7% | -435.09M▲ 9.1% | -417.54M▲ 4.0% | -434.37M▲ 0% |
Pretax Margin % | -166.96% | -92.92% | -32.52% | -85.76% | -102.89% | -145.36% | -84.9% | -58.87% | -42.52% | -40.21% |
Income Tax | 7K | 38K | -1.87M | 379K | 300K | 1.14M | 685K | 1.28M | -1.26M | -1.18M |
Effective Tax Rate % | -0.01% | -0.05% | 2.68% | -0.15% | -0.08% | -0.17% | -0.14% | -0.3% | 0.3% | 0.27% |
Net Income | -83.22M▲ 0% | -85.06M▼ 2.2% | -75.65M▲ 11.1% | -253.78M▼ 235.5% | -405.67M▼ 59.8% | -654.59M▼ 61.4% | -479.45M▲ 26.8% | -436.37M▲ 9.0% | -416.28M▲ 4.6% | -433.19M▲ 0% |
Net Margin % | -166.97% | -93.85% | -35.29% | -88.51% | -108.57% | -145.61% | -85.02% | -59.05% | -42.39% | -40.1% |
Net Income Growth % | -80.37% | -2.21% | 11.06% | -235.47% | -59.85% | -61.36% | 26.76% | 8.98% | 4.61% | -4% |
Net Income (Continuing) | -83.22M | -84.26M | -67.85M | -246.28M | -384.77M | -654.59M | -479.45M | -436.37M | -416.28M | -433.19M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 41.8M | 49.6M | 57.1M | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.18▲ 0% | -1.00▲ 15.3% | -0.75▲ 25.0% | -2.53▼ 237.3% | -3.80▼ 50.2% | -6.41▼ 68.7% | -4.28▲ 33.2% | -3.56▲ 16.8% | -3.32▲ 6.7% | -3.30▲ 0% |
EPS Growth % | 66.19% | 15.25% | 25% | -237.33% | -50.2% | -68.68% | 33.23% | 16.82% | 6.74% | 0% |
EPS (Basic) | -1.18 | -1.00 | -0.75 | -2.53 | -3.80 | -6.41 | -4.28 | -3.56 | -3.32 | - |
Diluted Shares Outstanding | 70.72M | 85.03M | 90.6M | 97.5M | 101.31M | 102.18M | 111.99M | 122.75M | 125.37M | 131.27M |
Basic Shares Outstanding | 70.72M | 85.03M | 90.6M | 97.5M | 101.31M | 102.18M | 111.99M | 122.75M | 125.37M | 131.27M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
GH Balance Sheet
Guardant Health, Inc. (GH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 242.94M | 468.99M | 597.36M | 1.89B | 1.11B | 1.19B | 1.35B | 1.06B | 1.47B | 1.37B |
Cash & Short-Term Investments | 221.32M | 418.96M | 522.8M | 1.79B | 932.75M | 1.01B | 1.17B | 839.98M | 1.2B | 1.1B |
Cash Only | 72.28M | 140.54M | 143.23M | 832.98M | 492.2M | 141.65M | 1.13B | 525.54M | 378.2M | 989.29M |
Short-Term Investments | 149.04M | 278.42M | 379.57M | 961.9M | 440.55M | 869.58M | 35.1M | 314.44M | 823.39M | 113.47M |
Accounts Receivable | 12.79M | 35.69M | 47.99M | 53.3M | 97.65M | 97.26M | 88.78M | 110.25M | 137.85M | 137.4M |
Days Sales Outstanding | 93.64 | 143.72 | 81.7 | 67.85 | 95.39 | 78.97 | 57.46 | 54.45 | 51.24 | 44.02 |
Inventory | 7.29M | 9.14M | 15.18M | 22.72M | 30.67M | 51.6M | 61.95M | 71.08M | 85.88M | 83.85M |
Days Inventory Outstanding | 84.12 | 77.17 | 78.35 | 89.6 | 91.09 | 120.48 | 99.59 | 89.53 | 89.81 | 82.85 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 31.51M | 27.74M | 33.8M | 40.72M | 43.49M |
Total Non-Current Assets | 100M | 118.41M | 365.18M | 383.42M | 1.09B | 418.39M | 439.31M | 430.5M | 547.61M | 547.79M |
Property, Plant & Equipment | 16.04M | 31M | 72.81M | 100.13M | 313.9M | 341.92M | 302.71M | 279.08M | 304.76M | 303.94M |
Fixed Asset Turnover | 3.11x | 2.92x | 2.94x | 2.86x | 1.19x | 1.31x | 1.86x | 2.65x | 3.22x | 3.62x |
Goodwill | 0 | 0 | 3.29M | 3.29M | 3.29M | 3.29M | 3.29M | 3.29M | 77.26M | 77.26M |
Intangible Assets | 8.74M | 7.8M | 15.41M | 16.16M | 14.21M | 11.73M | 8.98M | 6.76M | 25.92M | 25.54M |
Long-Term Investments | 73.25M | 77.56M | 268.78M | 246.6M | 698.03M | 0 | 0 | 0 | 0 | 252.04M |
Other Non-Current Assets | 1.97M | 2.05M | 4.88M | 17.25M | 60.94M | 61.45M | 124.33M | 141.37M | 139.67M | 141.04M |
Total Assets | 342.94M▲ 0% | 587.4M▲ 71.3% | 962.53M▲ 63.9% | 2.27B▲ 136.0% | 2.2B▼ 3.0% | 1.61B▼ 27.0% | 1.79B▲ 11.0% | 1.49B▼ 16.8% | 2.01B▲ 35.5% | 1.92B▲ 0% |
Asset Turnover | 0.15x | 0.15x | 0.22x | 0.13x | 0.17x | 0.28x | 0.32x | 0.50x | 0.49x | 0.66x |
Asset Growth % | 194.2% | 71.29% | 63.86% | 136.02% | -2.96% | -26.97% | 10.96% | -16.84% | 35.54% | 43.77% |
Total Current Liabilities | 19.63M | 46.94M | 72.73M | 66.81M | 194.69M | 193.22M | 205.92M | 225.58M | 302.73M | 292.14M |
Accounts Payable | 5M | 10.64M | 16.2M | 7.34M | 38.52M | 68.91M | 51.74M | 38.55M | 54.44M | 75.03M |
Days Payables Outstanding | 57.7 | 89.89 | 83.6 | 28.95 | 114.38 | 160.9 | 83.18 | 48.55 | 56.94 | 46.78 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29.21M | 0 | 0 |
Deferred Revenue (Current) | 3.11M | 16.14M | 12.28M | 8.55M | 11.33M | 17.4M | 17.96M | 35.47M | 50.75M | 199.74M |
Other Current Liabilities | 4.91M | 12.99M | 18.56M | 28.28M | 120.5M | 55.79M | 72.74M | 39.13M | 197.53M | 169.34M |
Current Ratio | 12.38x | 9.99x | 8.21x | 28.27x | 5.72x | 6.17x | 6.54x | 4.68x | 4.84x | 4.68x |
Quick Ratio | 12.01x | 9.80x | 8.00x | 27.93x | 5.57x | 5.90x | 6.24x | 4.36x | 4.56x | 4.39x |
Cash Conversion Cycle | 120.07 | 131 | 76.46 | 128.5 | 72.1 | 38.54 | 73.87 | 95.43 | 84.11 | 80.08 |
Total Non-Current Liabilities | 14.71M | 15.51M | 41.81M | 849.38M | 1.36B | 1.36B | 1.42B | 1.4B | 1.81B | 1.8B |
Long-Term Debt | 0 | 0 | 0 | 806.29M | 1.13B | 1.14B | 1.14B | 1.14B | 1.68B | 1.68B |
Capital Lease Obligations | 460K | 0 | 33.26M | 41.56M | 226.05M | 210.01M | 185.85M | 164.29M | 0 | 377.74M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 14.24M | 15.51M | 8.55M | 1.52M | 3.93M | 9.18M | 96.01M | 92.83M | 127.77M | 127.69M |
Total Liabilities | 34.33M | 62.45M | 114.54M | 916.19M | 1.56B | 1.55B | 1.63B | 1.63B | 2.11B | 2.1B |
Total Debt | 659K | 0 | 40.4M | 854.49M | 1.37B | 1.37B | 1.35B | 1.34B | 1.68B | 1.68B |
Net Debt | -71.62M | -140.54M | -102.83M | 21.51M | 881.53M | 1.23B | 220.23M | 810.51M | 1.3B | 687.24M |
Debt / Equity | 0.00x | - | 0.05x | 0.63x | 2.13x | 22.75x | 8.53x | - | - | -9.26x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.10x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.68x |
Interest Coverage | -29.80x | -66.33x | -58.04x | -50.60x | -148.19x | -252.57x | -184.71x | -167.57x | -106.14x | -96.55x |
Total Equity | 308.61M▲ 0% | 524.95M▲ 70.1% | 847.99M▲ 61.5% | 1.36B▲ 59.9% | 645M▼ 52.4% | 60.18M▼ 90.7% | 158.68M▲ 163.7% | -139.65M▼ 188.0% | -99.31M▲ 28.9% | -181.07M▲ 0% |
Equity Growth % | 287.23% | 70.1% | 61.54% | 59.86% | -52.42% | -90.67% | 163.68% | -188% | 28.89% | -19271.47% |
Book Value per Share | 4.36 | 6.17 | 9.36 | 13.90 | 6.37 | 0.59 | 1.42 | -1.14 | -0.79 | -1.38 |
Total Shareholders' Equity | 308.61M | 483.15M | 798.39M | 1.3B | 645M | 60.18M | 158.68M | -139.65M | -99.31M | -181.07M |
Common Stock | 0 | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K | 1K |
Retained Earnings | -195.74M | -280.8M | -352.81M | -606.59M | -1.01B | -1.66B | -2.14B | -2.58B | -2.99B | -3.11B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -532K | -83K | 1.11M | 2.7M | -4.76M | -19.52M | -3.67M | -5.2M | -4.85M | -5.15M |
Minority Interest | 0 | 41.8M | 49.6M | 57.1M | 0 | 0 | 0 | 0 | 0 | 0 |
GH Cash Flow Statement
Guardant Health, Inc. (GH) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -72.23M | -72.19M | -47.13M | -103.93M | -209.02M | -309.46M | -324.98M | -239.86M | -184.76M | -175.41M |
Operating CF Margin % | -144.93% | -79.64% | -21.99% | -36.25% | -55.94% | -68.84% | -57.63% | -32.46% | -18.81% | - |
Operating CF Growth % | -96.77% | 0.07% | 34.7% | -120.49% | -101.12% | -48.06% | -5.01% | 26.19% | 22.97% | 140% |
Net Income | -83.22M | -84.26M | -67.85M | -246.28M | -384.77M | -654.59M | -479.45M | -436.37M | -416.28M | -433.19M |
Depreciation & Amortization | 5.21M | 7.14M | 11.41M | 16.07M | 22.27M | 35.96M | 42.88M | 42.39M | 39.74M | 38.94M |
Stock-Based Compensation | 3.67M | 6.85M | 16.95M | 144.11M | 151.45M | 94.69M | 90.76M | 140.41M | 166.22M | 132.88M |
Deferred Taxes | 0 | 0 | -1.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 7.1M | -782K | 2.25M | 29.84M | 42.5M | 152.91M | -33.01M | 74.58M | 15.78M | 100.33M |
Working Capital Changes | -4.99M | -1.13M | -8.3M | -47.66M | -40.47M | 61.56M | 53.84M | -60.86M | 9.78M | -14.36M |
Change in Receivables | -9.29M | -22.9M | -7.39M | -5.46M | -44.35M | 375K | 8.38M | -21.39M | -28.18M | -21.12M |
Change in Inventory | -4.52M | -1.85M | -6.04M | -7.54M | -7.96M | -20.93M | -10.35M | -9.13M | -14.79M | -6.59M |
Change in Payables | 1.25M | 5.05M | 4.34M | -7.86M | 8.64M | 60.33M | 0 | -2.82M | 52.75M | 46.06M |
Cash from Investing | -170.42M | -153.03M | -317.57M | -617.09M | -63.16M | 149.82M | 840.25M | -261.31M | -627.2M | -230.65M |
Capital Expenditures | -6.68M | -20.2M | -18.72M | -36.17M | -75.03M | -77.46M | -20.49M | -35.09M | -48.31M | -49.43M |
CapEx % of Revenue | 13.4% | 22.29% | 8.73% | 12.62% | 20.08% | 17.23% | 3.63% | 4.75% | 4.92% | 4.58% |
Acquisitions | 0 | 0 | -7.33M | 0 | 0 | 0 | 0 | 0 | -58.99M | -58.99M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -2.3M | 0 | -2.57M | -17.89M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 281.66M | 293.16M | 367.3M | 1.41B | -66.82M | -189.09M | 477.38M | -996K | 671.13M | 704.12M |
Debt Issued (Net) | -26.09M | -443K | -438K | 1.13B | -146K | -71K | 0 | 0 | 0 | 372.84M |
Equity Issued (Net) | 306.98M | 253.83M | 350.43M | 355.73M | 0 | 0 | 493.12M | 14.84M | 101.46M | 368.05M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -7.22M | -172K | 0 | 0 | 0 | 0 | 0 | 0 | 13.59M | 0 |
Other Financing | 765K | 39.77M | 17.31M | -78M | -66.68M | -189.02M | -15.74M | -15.83M | 569.68M | -36.77M |
Net Change in Cash | 39.01M▲ 0% | 67.95M▲ 74.2% | 2.68M▼ 96.0% | 689.75M▲ 25598.5% | -340.69M▼ 149.4% | -350.34M▼ 2.8% | 991.74M▲ 383.1% | -503.93M▼ 150.8% | -140.34M▲ 72.2% | 295.88M▲ 0% |
Free Cash Flow | -81.22M▲ 0% | -92.39M▼ 13.8% | -68.42M▲ 25.9% | -157.99M▼ 130.9% | -284.05M▼ 79.8% | -386.92M▼ 36.2% | -345.46M▲ 10.7% | -274.94M▲ 20.4% | -233.07M▲ 15.2% | -224.83M▲ 0% |
FCF Margin % | -162.95% | -101.93% | -31.92% | -55.1% | -76.02% | -86.07% | -61.26% | -37.2% | -23.73% | -20.81% |
FCF Growth % | -111.09% | -13.75% | 25.94% | -130.91% | -79.8% | -36.22% | 10.72% | 20.41% | 15.23% | 26.25% |
FCF per Share | -1.15 | -1.09 | -0.76 | -1.62 | -2.80 | -3.79 | -3.08 | -2.24 | -1.86 | -1.71 |
FCF Conversion (FCF/Net Income) | 0.87x | 0.85x | 0.62x | 0.41x | 0.52x | 0.47x | 0.68x | 0.55x | 0.44x | 0.52x |
Interest Paid | 1.34M | 1.25M | 1.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 26K | 102K | 298K | 331K | 393K | 1.33M | 1.97M | 1.01M | 0 | 0 |
GH Key Ratios
Guardant Health, Inc. (GH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -42.86% | -20.41% | -11.02% | -23.03% | -40.55% | -185.65% | -438.12% | -4584.47% | - | 184.27% |
Return on Invested Capital (ROIC) | -38.29% | -22.44% | -10.94% | -18.02% | -21.23% | -29.01% | -50.82% | -63.38% | -34.89% | -53.65% |
Gross Margin | 36.56% | 52.33% | 67.01% | 67.73% | 67.11% | 65.23% | 59.74% | 60.79% | 64.46% | 64.9% |
Net Margin | -166.97% | -93.85% | -35.29% | -88.51% | -108.57% | -145.61% | -85.02% | -59.05% | -42.39% | -40.1% |
Debt / Equity | 0.00x | - | 0.05x | 0.63x | 2.13x | 22.75x | 8.53x | - | - | -9.26x |
Interest Coverage | -29.80x | -66.33x | -58.04x | -50.60x | -148.19x | -252.57x | -184.71x | -167.57x | -106.14x | -96.55x |
FCF Conversion | 0.87x | 0.85x | 0.62x | 0.41x | 0.52x | 0.47x | 0.68x | 0.55x | 0.44x | 0.52x |
Revenue Growth | 97.4% | 81.85% | 136.52% | 33.75% | 30.32% | 20.31% | 25.45% | 31.04% | 32.88% | 39.56% |
Related:GH Dividend History·GH Revenue History·GH Price History·GH P/E History·GH Financial Ratios·GH Institutional Holders
GH SEC Filings & Documents
Guardant Health, Inc. (GH) SEC filings — annual & quarterly reports (10-K, 10-Q)
GH Frequently Asked Questions
Guardant Health, Inc. (GH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Guardant Health, Inc. (GH) reported $1.08B in revenue for fiscal year 2025. This represents a 4178% increase from $25.2M in 2016.
Guardant Health, Inc. (GH) grew revenue by 32.9% over the past year. This is strong growth.
Guardant Health, Inc. (GH) reported a net loss of $433.2M for fiscal year 2025.
Dividend & Returns
Guardant Health, Inc. (GH) had negative free cash flow of $224.8M in fiscal year 2025, likely due to heavy capital investments.